Fluindione and drug reaction with eosinophilia and systemic symptoms: an unrecognised adverse effect?

Daveluy, Amélie; Milpied, B.; Barbaud, A.; Lebrun‐Vignes, Bénédicte; Gouraud, Aurore; Laroche, Marie‐Laure; Ciobanu, Ecaterina; Bégaud, Bernard; Moore, Nicholas; Miremont-Salamé, Ghada; Haramburu, Françoise

doi:10.1007/s00228-011-1101-9

Cited by 7 publications

(4 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many studies have reported positive PTs with carbamazepine at 10% or 30%, including 11 cases among 13 patients with DRESS possibly due to this anticonvulsant in the present study, seven out of 10 suspected cases in the study of Lin et al, 17 and 13 ⁄18 cases (at 20% in petrolatum) reported by Santiago et al 3 There are also some reports of positive drug PTs in patients with DRESS 2 in response to abacavir, 18 antituberculous agents, 19 aspirin, 20 carbamazepine, 17,21 cyclins, beta-lactam antibiotics, 9,22 celecoxib, 19 esomeprazole, 22 fluindione, 23 lamotrigine, 2 phenytoin, 3 propylthiouracil, 24 spironolactone and topiramate. 3 In DRESS, herpes family virus reactivation has been reported in 76% of patients, and the main response may be related to an expansion of CD8+ T cells directed against EBV or HHV-6.…”

Section: Discussionsupporting

confidence: 57%

See 1 more Smart Citation

A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions

Barbaud

Collet

Milpied

et al. 2013

British Journal of Dermatology

333

272

View full text Add to dashboard Cite

SummaryBackground Drug patch tests (PTs) can reproduce delayed hypersensitivity to drugs and entail a moderate re-exposure of patients to offending drugs. Objectives To determine the value of PTs for identifying the responsible drug in severe cutaneous adverse drug reactions (SCARs) such as acute generalized exanthematous pustulosis (AGEP), drug reaction with eosinophilia and systemic symptoms (DRESS) and Stevens-Johnson syndrome ⁄toxic epidermal necrolysis (SJS ⁄TEN). Methods In a multicentre study, PTs were conducted on patients referred for DRESS, AGEP or SJS ⁄TEN within 1 year of their SCAR. All drugs administered in the 2 months prior to and the week following the onset of the SCAR were tested. Results Among the 134 patients included (48 male, 86 female; mean age 51AE7 years), positive drug PTs were obtained for 24 different drugs. These included positive tests for 64% (46 ⁄72) of patients with DRESS, 58% (26 ⁄45) of those with AGEP and 24% (4 ⁄17) of those with SJS ⁄TEN, with only one relapse of AGEP. The value of PTs depended on the type of drug and the type of SCAR (e.g. carbamazepine was positive in 11 ⁄13 DRESS cases but none of the five SJS ⁄TEN cases). PTs were frequently positive for beta lactams (22 cases), pristinamycin (11 cases) and in DRESS with pump proton inhibitors (five cases), but were usually negative for allopurinol and salazopyrin. Of 18 patients with DRESS, eight had virus reactivation and positive PTs. In DRESS, multiple drug reactivity was frequent (18% of cases), with patients remaining sensitized many years later. Conclusions PTs are useful and safe for identifying agents inducing SCAR.

show abstract

Section: Discussionsupporting

confidence: 57%

“…There are also some reports of positive drug PTs in patients with DRESS 2 in response to abacavir, 18 antituberculous agents, 19 aspirin, 20 carbamazepine, 17,21 cyclins, beta‐lactam antibiotics, 9,22 celecoxib, 19 esomeprazole, 22 fluindione, 23 lamotrigine, 2 phenytoin, 3 propylthiouracil, 24 spironolactone and topiramate 3 …”

Section: Discussionmentioning

confidence: 99%

A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions

Barbaud

Collet

Milpied

et al. 2013

British Journal of Dermatology

333

272

View full text Add to dashboard Cite

show abstract

“…[ 5 ] Association of DRESS syndrome to fluindione was first desbribed by Sparsa et al [ 6 ] Since then, 36 cases of DRESS syndrome associated to fluindione were reported in a 10 years period. [ 7 ] The mean time-to-onset of DRESS syndrome after fluindione treatment was 28.4 days; occurrence was more rapid in patients with previous hypersensitivity syndrome with a chemically related drug. Kidneys and liver were the most frequently involved organs, but no cases of cardiac involvement were observed.…”

Section: Discussionmentioning

confidence: 99%

DRESS syndrome with thrombotic microangiopathy revealing a Noonan syndrome

Bobot

Coen

Simon³

et al. 2018

Medicine

View full text Add to dashboard Cite

Rationale:The life-threatening drug rash with eosinophilia and systemic symptoms (DRESS) syndrome occurs most commonly after exposure to drugs, clinical features mimic those found with other serious systemic disorders. It is rarely associated with thrombotic microangiopathy.Patient concerns:We describe the unique case of a 44-year-old man who simultaneously experienced DRESS syndrome with thrombotic microangiopathy (TMA) after a 5 days treatment with fluindione.Diagnoses:Clinical evaluation leads to the discovery of an underlying lymphangiomatosis, due to a Noonan syndrome.Intervetions:The anticoagulant was withdrawn, and corticosteroids (1 mg/kg/day) and acenocoumarol were started.Outcomes:Clinical improvement ensued. At follow-up the patient is well.Lessons:The association of DRESS with TMA is a rare condition; we believe that the presence of the underlying Noonan syndrome could have been the trigger. Moreover, we speculate about the potential interrelations between these entities.

show abstract

“…However, this activity can also be used as treatment for vitamin K antagonists (VKAs), as observed for phenindione derivatives (see Scheme 179) [449]. However, pheindione is not so much used anymore and was replaced by its homologue, fluindione, or other coumarins VKA due to side effects such as hypersensitivity identified for pheindione [450]. However, despite a proven efficiency as vitamin K epoxide reductase, fluindione 609b is used almost only in France because of a lack of study data on old people [451].…”

Section: Indane-13-dione As Anticoagulant Drugsmentioning

confidence: 99%

Indane-1,3-Dione: From Synthetic Strategies to Applications

2022

View full text Add to dashboard Cite

Indane-1,3-dione is a versatile building block used in numerous applications ranging from biosensing, bioactivity, bioimaging to electronics or photopolymerization. In this review, an overview of the different chemical reactions enabling access to this scaffold but also to the most common derivatives of indane-1,3-dione are presented. Parallel to this, the different applications in which indane-1,3-dione-based structures have been used are also presented, evidencing the versatility of this structure.

show abstract

Fluindione and drug reaction with eosinophilia and systemic symptoms: an unrecognised adverse effect?

Cited by 7 publications

References 18 publications

A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions

A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions

DRESS syndrome with thrombotic microangiopathy revealing a Noonan syndrome

Indane-1,3-Dione: From Synthetic Strategies to Applications

Contact Info

Product

Resources

About